GlobeNewswire Inc | Oct 7, 2021 08:00AM EDT

October 07, 2021

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that onOctober 1, 2021,the compensation committee of GBTs board of directors granted22 new employees restricted stock units for an aggregate of 54,750 shares of the companys common stock. These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).

The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBTs board of directors in January 2017 and has been amended and restated from time to time.

About Global Blood TherapeuticsGlobal Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the companys next-generation hemoglobin S polymerization inhibitor. In addition, GBTs drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:Steven Immergut (media)650-410-3258simmergut@gbt.com

Courtney Roberts (investors)650-351-7881croberts@gbt.com